Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion
Rheumatology Advances in Practice · 14.03.2025 · 9 (2)
DOI: 10.1093/rap/rkaf048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 04.06.2025. Verfasst von Sander I van Leuven und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Patients with systemic lupus erythematosus (SLE) have increased risk of developing atherosclerotic cardiovascular disease (ASCVD). This excessive risk starts to accumulate during the earliest stages of SLE. ASCVD in SLE is associated with an adverse outcome. SLE-enhanced atherogenesis is most likely the consequence of a complex interplay between traditional risk factors and chronic auto-immune inflammation. This underscores the importance of conscientious management of traditional risk factors as well as maintaining low SLE disease activity. Shared immune pathways in SLE and ASCVD can affect the vascular biology of the atherosclerotic process in patients with SLE. In this review, we will discuss how the ASCVD risk evolves during the SLE disease course, and we consider whether patients with SLE are prone to developing superficial erosion of atherosclerotic plaques. This is highly relevant as pilot studies in the general population suggest antithrombotic therapy without stenting could be the better therapeutic approach in patients with plaque erosion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
- Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.
- Tennessee Valley Healthcare System, U.S. Department of Veterans Affairs, Nashville, TN, USA.
ORCID-Profile: Sander I van Leuven
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
van Leuven, S. I., van Bon, L., Nijveldt, R., & Major, A. S. (2025). Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion. Rheumatology Advances in Practice, 9(2). https://doi.org/10.1093/rap/rkaf048
Vancouver
van Leuven SI, van Bon L, Nijveldt R, Major AS. Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion. Rheumatology Advances in Practice. 2025;9(2). doi:10.1093/rap/rkaf048
BibTeX
@article{vanLeuven2025,
author = {van Leuven, Sander I and van Bon, Lenny and Nijveldt, Robin and Major, Amy S},
title = {Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion},
journal = {Rheumatology Advances in Practice},
year = {2025},
volume = {9},
number = {2},
doi = {10.1093/rap/rkaf048}
}
EUVIMED